text: << Sorafenib >> and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta ([[ PDGFR-beta ]]), while temsirolimus is an mTOR inhibitor.